Eli Lilly announced plans to increase drug prices in Europe and other developed markets as a strategic response to U.S. policy pressures, including President Trump's expressed desire for lower drug prices domestically and higher prices abroad. The price hike notably affects the diabetes medication Mounjaro, which has nearly tripled in cost in the UK. This move is linked to efforts to counter the U.S. Most Favored Nation (MFN) policy. Additionally, Eli Lilly recently signed a $1.3 billion deal with Superluminal. Meanwhile, the U.S. Department of Health and Human Services (HHS) is reviving a vaccine task force. In oncology news, Nemvaleukin alfa has demonstrated durable disease control in advanced melanoma and renal cell carcinoma. Texas has also filed a lawsuit against Eli Lilly over alleged kickbacks. Other biotech developments include a downturn in Novo Nordisk's GLP-1 market and increased activity in biotech acquisitions.